TOP HEADLINES

Featured Story

Novartis bids farewell to vaccines with $7.1B sale to GSK

After years of struggles and months of speculation, Novartis is finally kissing its vaccines unit goodbye. As part of a company-wide revamp, the Swiss drugmaker will send the division to the U.K., where GlaxoSmithKline will be waiting with open arms to take on a vaccines business that will give it an edge in meningitis and bolster its pipeline.

U.K. health secretary asks Novartis CEO for Bexsero price cut

When a U.K. advisory committee reversed its earlier guidance and recommended the country's National Health Service add Novartis' meningitis B vaccine Bexsero to its national immunization program, it did so on condition that the NHS secure a "cost-effective price" for the jab. And now, it seems the country and the Swiss company may have different ideas of what that price should be.

Merck, Sanofi hope for sales expansion with two-dose Gardasil switch

Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck and Sanofi will see the number of shots per patient fall. But that doesn't mean they'll necessarily take a sales hit, with the move potentially expanding overall access and providing a bump both drugmakers could use.

Sanofi and Pitt join up to test wannabe dengue blockbuster

Sanofi's dengue fever candidate is on the verge of regulatory applications after 20 years in the lab and more than $1.4 billion spent on R&D. Now the pharma giant has forged a new collaboration to help assess the jab's postintroduction effectiveness.

New Novartis director will implement Bexsero on U.K. immunization program

Dr. John Porter, formerly the U.K. medical team lead for Pfizer, will become Novartis' medical affairs director for Northern Europe.

MORE NEWS

From Our Sister Sites

FierceDrugDelivery

Researchers at Harvard University's Wyss Institute have developed "smart" nanoparticles out of DNA that act like a virus to bypass the body's immune system's defenses and deliver drugs to a tumor.

FiercePharma

Amgen reported a mixed bag of results in the first earnings period following its acquisition of Onyx Pharmaceuticals. First-quarter revenues came in approximately $230 million lower than consensus, a miss that the company attributes primarily to sluggish sales of Enbrel.